<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="586">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01700179</url>
  </required_header>
  <id_info>
    <org_study_id>ACH102-005</org_study_id>
    <nct_id>NCT01700179</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety Tolerability and Antiviral Activity of ACH-0143102 Plus RBV Treatment Naive HCV GT1b Subjects</brief_title>
  <official_title>A Phase 1b, Open-label, Pilot Study to Evaluate the Safety, Tolerability and Antiviral Activity of Oral ACH-0143102 Administered in Combination With Ribavirin for 12 Weeks in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection Genotype 1b.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achillion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achillion Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and efficacy of 12 weeks
      of treatment with ACH-0143102 and ribavirin in GT1b, treatment-naive, HCV subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 1b, pilot study to evaluate the safety, tolerability and antiviral activity of oral
      ACH-0143102 administered in combination with ribavirin for 12 weeks in treatment naive
      subjects with chronic hepatitis C virus infection genotype 1b.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>SVR12</measure>
    <time_frame>12 weeks following last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the incidence of a sustained virologic response at 12 weeks after the completion of dosing (SVR12) with ACH-0143102 plus ribavirin, reported as HCV RNA less than the limit of quantification (&lt;LOQ) at that time point</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>ACH-0143102 plus ribavirin daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACH-0143102 225 mg loading dose on Day 1 followed by 75 mg maintenance dose on Days 2-84. Weight-based RBV(as per label) for Days 1-84.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH-0143102</intervention_name>
    <arm_group_label>ACH-0143102 plus ribavirin daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <arm_group_label>ACH-0143102 plus ribavirin daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 18 years and older

          -  Clinical diagnosis of hepatitis C with genotype 1b

          -  Chronic hepatitis C treatment naive subjects

          -  IL28B genotype CC

          -  HCV RNA &gt; 10000 IU/mL at screening

          -  Females must be willing to use two effective methods of contraception during dosing
             period and for six months after the last dose of ribavirin.

          -  Male patients must be willing to use an effective barrier method of contraception
             throughout the dosing period and for six months after the last dose of ribavirin.
             Males must agree to not donate sperm while enrolled in the study and for six months
             after the last dose of ribavirin.

          -  Willing to participate in all study activities and all study requirements.

        Exclusion Criteria:

          -  BMI&gt;36

          -  Pregnant or nursing females

          -  Clinically significant laboratory abnormalities at screening

          -  Previous participation in a clinical trial with protease inhibitor and/or NS5A
             inhibitor

          -  HIV infection or other liver diseases

          -  Positive Hepatitis B Surface Antigen

          -  Liver cirrhosis

          -  Uncontrolled psychiatric disease

          -  Clinical evidence of chronic cardiac disease

          -  History of malignancy of any organ system within 5 years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dr. Aasim Sheikh</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Robert Herring Jr</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victor Ankoma-Sey</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinod Rustgi, MD</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Brennan</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael Ryan, MD</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <lastchanged_date>October 2, 2014</lastchanged_date>
  <firstreceived_date>October 2, 2012</firstreceived_date>
  <firstreceived_results_date>September 30, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
